Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) EBITDA (2018 - 2025)

TELA Bio (TELA) has 8 years of EBITDA data on record, last reported at -$8.6 million in Q3 2025.

  • For Q3 2025, EBITDA rose 16.63% year-over-year to -$8.6 million; the TTM value through Sep 2025 reached -$39.1 million, up 5.91%, while the annual FY2024 figure was -$37.8 million, 19.01% up from the prior year.
  • EBITDA reached -$8.6 million in Q3 2025 per TELA's latest filing, up from -$9.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.7 million in Q1 2024 and bottomed at -$12.9 million in Q4 2023.
  • Average EBITDA over 5 years is -$9.6 million, with a median of -$9.8 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 53.1% in 2024, then tumbled 99.17% in 2025.
  • A 5-year view of EBITDA shows it stood at -$7.7 million in 2021, then fell by 23.32% to -$9.4 million in 2022, then plummeted by 37.03% to -$12.9 million in 2023, then increased by 28.35% to -$9.3 million in 2024, then grew by 7.14% to -$8.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$8.6 million in Q3 2025, -$9.9 million in Q2 2025, and -$11.3 million in Q1 2025.